# Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

> **NCT03770455** · PHASE2 · TERMINATED · sponsor: **Jodi Layton, MD** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** 2nd generation ADT (abiraterone or enzalutamide)

## Key facts

- **NCT ID:** NCT03770455
- **Lead sponsor:** Jodi Layton, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-25
- **Primary completion:** 2020-12-17
- **Final completion:** 2021-01-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Early signs of progression and learned experience that the assumed time period between psa progression and radiographic progression was shorter than expected
- **Last updated:** 2024-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03770455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03770455, "Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03770455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*